No Data
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth
LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $38
LifeSci Capital analyst Sam Slutsky maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 47.5%
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $36
Citi analyst Yigal Nochomovitz maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and adjusts the target price from $30 to $36.According to TipRanks data, the analyst has a success rate of 44.
ArriVent BioPharma, Inc.: Strong Clinical Data and Improved Financial Outlook Prompt Buy Rating and Price Target Increase
ArriVent BioPharma Is Maintained at Buy by Goldman Sachs
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $39
Oppenheimer analyst Jeff Jones maintains $ArriVent BioPharma(AVBP.US)$ with a buy rating, and adjusts the target price from $35 to $39.According to TipRanks data, the analyst has a success rate of 41.
No Data
No Data